NEPH Nephros, Inc.
$2.61
Nephros, Inc. Q3 F2026 Earnings Call Transcript
AI Conference Call Analysis
Sign in or subscribe to read.Colby
Conference Call Operator
I'll now turn the call over to Kieran Smith.
Colby
Conference Call Operator
You may begin.
Kieran Smith
PCG Advisory
Thank you, everyone, and good afternoon. This is Kieran Smith with PCG Advisory. Thank you all for participating in NEFROS' third quarter 2026 conference call. Before we begin, I would like to caution that comments made during this conference call made by management will contain forward-looking statements regarding the operations and future results of NEFROS. I encourage you to review Nefros' filings with the Securities and Exchange Commission, including, without limitation, the company's forms 10-K and 10-Q, to identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements. Factors that may affect the company's results include, but are not limited to, Nefros' ability to successfully, timely, and cost-effectively market and sell its products and service offerings, the rate of adoption of its products and services by hospitals and other healthcare providers, the success of its commercialization efforts, and the effect of existing and new regulatory requirements on NEPHRO's business and other economic and competitive factors. The content of this conference call contains time-sensitive information that is accurate only as of the date of the live call, today, November 6, 2026. Company undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this conference call, except as required by law. I would now like to turn the call over to NEFROS's President and Chief Executive Officer, Robert Banks. Robert, please go ahead.
Robert Banks
President and Chief Executive Officer
Thank you, Kieran, and good afternoon, everyone. The third quarter of 2026 was another strong quarter for NEFROS, and more importantly, provides additional evidence of the durability of the growth we have been building over the last several years. We generated approximately $5.6 million in revenue, an increase of 18% over the third quarter of 2025. This followed the record $6 billion we reported in the second quarter. I think that sequence is important. Our record quarter is exciting. Following a record quarter with another quarter of strong double-digit year-over-year growth tells us much more about the underlying business. For the first nine months of 2026, revenue reached approximately $15.9 million, an increase of 20% over the same period last year. Core programmatic revenue increased 19% over that nine-month period. Importantly, This is profitable revenue growth where net income and adjusted EBITDA increase prospectively to approximately $500,000 and approximately $600,000. Our trailing 12-month revenue has now surpassed $21 million. When you look at those results together, I believe they demonstrate that Nepros is becoming a larger, stronger, and increasingly durable business. Our core programmatic business remains the foundation of that growth. Programmatic product revenue increased approximately 8% during the third quarter compared with last year. That business is particularly important to us because it represents customers incorporating their first products into their operations and then purchasing replacement filters over time. Every new installation has the potential to contribute to future recurring demand. Emergency response also contributed meaningfully during the quarter. As we have discussed several times, emergency response will fluctuate depending on outbreaks, infrastructure issues, and other urgent water quality events. We don't build our long-term growth strategy around emergencies, but the ability to respond quickly when customers need us remains an important part of what differentiates Nepros. Service revenue also continued to grow. We increasingly see customers looking to Nepros not only to provide filtration products, but to also help install them, replace them, and support the filtration component of the broader water management programs. That brings me to another encouraging indicator from the quarter, the continued expansion of our customer base. We ended Q3 with a record 1,766 active customer sites, having added approximately 31 in Q3 alone. Healthcare remains at the center of NEPROS, representing 64% of new sites added during the quarter. But we are also seeing the technology find applications outside of our traditional healthcare business. Approximately 17% of new sites came from commercial and industrial customers, with the remainder representing government, military, hospitality, residential, retail, and other applications. I believe that diversification is important. Our objective is to not move away from healthcare, because healthcare remains our largest market and an area we believe substantial opportunity remains. Instead, we are taking the technology, expertise, and reputation we have built in a demanding healthcare environment and identifying additional applications where water quality matters. We continue to monitor emerging industry standards, regulatory developments, and market intelligence to unmet needs and determine where nephros technology can provide meaningful value. That approach has already helped us expand our product portfolio into applications involving sterile processing, PFAS, microplastics, and nanoplastics, as well as drinking water, commercial filtration, and other emerging water quality challenges. At the same time, our strategy continues to evolve beyond products alone. We've talked previously about the three pillars we are building around Nephros, products, service, education. Products remains the foundation. Service makes these products easier for customers to adopt and maintain, and education is increasingly helping us create relationships earlier in the decision-making process. During the third quarter, the Nefros Water Institute continued a strong series of educational webinars addressing water quality issues relevant to healthcare professionals and other customers. We believe this is becoming an increasingly important part of our commercial strategy. Education allows us to engage customers and industry professionals around emerging water quality challenges share expertise we have accumulated over many years and build relationships well before someone is ready to make a filtration decision. Our goal isn't simply to conduct webinars. The goal is to make NEPROS a trusted resource for water quality information. When we educate the market effectively, we increase awareness of water safety challenges and potential solutions. That creates engagement, generates Thank you for joining us today. Several factors continue to affect margins, including shipping and handling costs, tariffs, and changes in revenue mix. Service is a good example of the trade-off involved. Service currently carries a lower gross margin percentage than our traditional infection control product business, but it generates incremental gross profit dollars, supports product sales, and removes barriers to adoption and can deepen customer relationships. So we continue to evaluate the business based not simply on maximizing a quarterly gross margin percentage, but also on creating sustainable, profitable growth. We remain focused on pricing, sourcing, freight, product mix, and operational efficiency while continue to invest where we believe these investments can create attractive long-term returns. Overall, I am very pleased with where we stand after 9-11. Revenue is up 20%. More programmatic revenue is up 19%. We increased our profitability. Our active customer sites have hit a record high level, which is very important because we've talked about that over and over again. Our service capabilities continue to expand. Our educational strategy is gaining momentum, and we continue to identify new applications for nephros technology. There is considerable work still ahead of us, but I believe we are entering the final quarter of 2026 for our position of strength. I want to thank the entire Nefros team for the tremendous amount of work behind these results, our customers and partners for their continued trust, and our shareholders for their support. With that, I will turn the call over to our CFO, Judy Krandel, for a closer look at the financial results.
Judy Krandel
Chief Financial Officer
Thank you, Robert. I will now provide a closer look at Nefros' financial performance for the third quarter and first nine months of 2026. Net revenue for the third quarter was approximately $5.6 million compared with approximately $4.8 million in the third quarter of 2025, an increase of 18%. The increase was driven primarily by growth in product revenue. Our core programmatic revenue increased approximately 8% compared with the prior year quarter. We also experienced significant growth in emergency response revenue and continued growth in service revenue. Cost of goods sold for the third quarter was approximately $2.3 million compared with approximately $1.8 million in the third quarter of 2025, an increase of 26%. Gross margin for the third quarter was approximately 58% compared with 61% during the same period last year. This approximately three percentage point decrease was primarily attributable to higher inventory, shipping, and handling costs, including tariff expense, as well as continued growth in service revenue, which currently carries a lower gross margin than our product sales. Selling, general, and administrative expenses were approximately $2.4 million compared with $2.2 million in the third quarter of 2025, an increase of about 9%. The increase was primarily attributable to increased headcount and professional fees. Research and development expense was approximately $331,000 compared with $338,000 in the prior year period, a decrease of about 2%. Depreciation and amortization expenses were approximately $29,000 compared with $34,000 in the third quarter of 2025. and consequently net income for the third quarter was approximately $500,000 compared with $300,000 during the same period in 2025. Adjusted EBITDA was approximately 600,000 compared with 400,000 in the third quarter of 2025. Now turning to our year-to-date results, net revenue for the nine months ended September 30th, 2026 was approximately $16.9 million compared with $14.1 million during the same period in 2025, an increase of 20%. Our core programmatic revenue increased approximately 19% over the first nine months of 2025, and this reflects continued reorder activity and expansion of our active customer base. Service revenues also experienced strong growth. and gross margin for the first nine months of 2026 was approximately 61% compared with about 63% for the same period in 2025. As we discussed during our second quarter call, our 2026 year to date gross margin benefited from approximately $600,000 of IEPA tariff refunds that were recognized during the second quarter. At the same time, margins have continued to experience pressure from increased product costs associated with foreign currency movements, tariffs, shipping expenses, and the rapid growth of commercial products and service revenue, which currently carry lower margins than our traditional infection control business. Selling general and administrative expenses for the first nine months of 2026 were approximately $7.4 million compared with about $6.7 million in the prior year period, an increase of about 10%, primarily due to increased headcount and professional fees. Research and development expenses were approximately $1 million compared with approximately $900,000 during the same period in 2025. And consequently, net income for the first nine months of 2026 increased to approximately $1.8 million. compared with about $1.1 million during the same period last year. Adjusted EBDA for the nine-month period increased to approximately $2 million compared with about $1.4 million in 2025. And as of September 30, 2026, NEPHROs had approximately $4.5 million in cash and cash equivalents and continued to remain debt-free. I will now like to turn the call back to Robert for closing remarks. Robert?
Robert Banks
President and Chief Executive Officer
Thank you, Judy. As we close today's prepared remarks, I want to leave investors with a few thoughts about what I believe the third quarter tells us about Nefros. First, the growth we are seeing is increasingly durable. We followed a record second quarter with another quarter of strong double-digit year-over-year growth, bringing revenue for the first nine months of 2026 to approximately $16.9 million. and more. Second, the foundation underneath that growth continues to expand. Core programmatic revenue is up 19% year to date. Our active customer base has reached a record 1,766 sites. And each new programmatic customer creates the potential for future replacement demand. Third, we are becoming a broader company. Healthcare remains our core market. but our products are increasingly finding applications across commercial, industrial, and other markets. And we're no longer thinking about Nephros as simply a company that manufactures and sells filters. We are building around three complementary capabilities, products, service, and education. Products solve the water quality problem.
Kieran Smith
PCG Advisory
Service helps customers successfully deploy and maintain those solutions.
Robert Banks
President and Chief Executive Officer
Education helps customers understand the problem in the first place and establishes Nefros as a trusted resource. We believe those three capabilities working together can create a stronger customer relationship, greater recurring demand, and a more differentiated company. Finally, we remain focused on profitable growth. We are proud of the strong margins we have and recognize the pressures that exist in the business today, and we're actively working on them. but we are also continuing to invest in capabilities that we believe are significantly larger over time. Our priorities remain straightforward. Take exceptional care of our existing customers, continue expanding our installed base, grow programmatic and service revenue, strengthen our educational platform, improve underlying margins, introduce differentiated products, and continue finding new applications and markets for our technology. Our objective for the remainder of 2026 is simple, finish strong. Most importantly, we want to enter 2027 with a large recurring revenue base, deeper customer relationship, and broader market opportunities and infrastructure necessary to support this stage of Nefros' growth. Thank you to our employees, customers, partners, and shareholders for your continued support. Operator, please open the line for questions.
Colby
Conference Call Operator
Thank you. We will now begin the question and answer session. If you'd like to ask a question at this time, please press star then the number one on your telephone keypad to raise your hand and enter the queue. If you'd like to withdraw your question at any time, you can simply press star one again. We'll pause just for a moment to compile the roster. And our first question comes from Bobby Brooks with Northland Capital Markets. Your line is open.
Bobby Brooks
Analyst, Northland Capital Markets
Hey, good afternoon, team. Thank you for taking my question. Robert, you mentioned how 17% of the new sites added for the programmatic business in the quarter were from commercial or industrial, and I wanted to unpack that a little bit more. First, could you speak to how the sales cycle on this might differ from your traditional healthcare end markets and what might Nefros be doing differently to target these accounts? Then I have a follow-up on that.
Robert Banks
President and Chief Executive Officer
Sure. 17% of new sites came from commercial and industrial customers. So that's our traditional commercial market, scale, odor, taste control. And the sales cycle doesn't differ tremendously from the infection control filters that we sell or in the healthcare space, except that what we sell is different, the competitors are different, and who we sell to typically is different. More often than not, we're working through partners when it comes to the commercial products. And partners that we've mentioned in the past are Donna Star, for example. And they've gotten some really good traction as they've got a new, renewed focus on where they're going and what they're selling to. They don't go site by site. They typically sell at a franchise level or a larger level. And what I've noticed is that they have a pretty slow adoption. so although it takes quite some time maybe six months maybe a year to actually close a enterprise level deal the adoption doesn't happen right away it will happen in several over period months and we notice that that revenue stream tends to trickle in and build up over time so i think what we're seeing today is more of efforts that have happened over the past year or two that are slowly gaining traction and getting in that those filters in place um but I think that answers the question. If not, I can definitely add more to it, but I don't want to over-answer.
Bobby Brooks
Analyst, Northland Capital Markets
I think that does it. You're speaking directly to commercial. Is that the same deal with industrial?
Robert Banks
President and Chief Executive Officer
Commercial or light industrial tends to be people with small manufacturing facilities. but the flow rates are typically pretty low. If it's a direct situation where we're not working through a partner, it's usually in conjunction with an infection control product, meaning they may want to control the taste, odor, and smell of an ice machine so they'll add one of these, a carbon filter in front. So it's not usually a different cell or a different person or a different timeline, just more products of our portfolio that we're selling. Increasingly, our sales managers across the regions are trying to incorporate our entire portfolio as well as our portfolio is getting larger and broader. We keep adding different capabilities such as PFOS and micro nanoplastics. So that might be contributing also to the diversification and more commercial filters entering the market space.
Bobby Brooks
Analyst, Northland Capital Markets
Got it. And then it kind of cuts down a little bit, but just so most of these sales into or most of these new sites for industrial and commercial, they're doing great. They're not ordering the infection prevention devices.
Robert Banks
President and Chief Executive Officer
I wouldn't characterize it that way. I would say that if the cell is from a direct cell, meaning nephros sold it not through a partner, it's almost always sold with or in conjunction with infection prevention. And if it's sold to a partner, they're selling usually at an enterprise or over multiple sites at one time level.
Bobby Brooks
Analyst, Northland Capital Markets
Got it. And have you talked about the split? Can you break down of the 17% cohort, how much of those were direct versus partner channel?
Robert Banks
President and Chief Executive Officer
No, I don't give that breakdown. It just was interesting to give a percentage of new customers. That's where that 17% number came out.
Bobby Brooks
Analyst, Northland Capital Markets
Yeah, I can appreciate that. and then maybe just one more for me as we kind of start to think about 2027 and next year is a growth strategy more of the same for you guys or are there any kind of interesting new products that you're excited to launch or just new strategies that you might be looking to implement just trying to get a sense of those drivers as we start to think about next year
Robert Banks
President and Chief Executive Officer
Yeah, so the strategies I mentioned today are new strategies. We don't launch one quarter and it's finished for the next quarter. They typically are multi-year efforts as it takes a long time to build markets, recognition, customer basis. But what is coming out of the strategies that we're executing today, especially when it comes to the education, is we're getting more feedback and hearing directly from industry professionals, professional organizations, and what they're giving us is Hey, here's our challenge. Here's what we can't really solve very easily today, which then in turn leads our R&D department to either apply what we've got already or come up with new ways to solve those problems. And that's what drives our NPI pipeline. But in every situation, I require a business case to show that if we do this, it's going to have a return that's attractive for NEPROS, and it is indeed the best place to spend our next dollar. So that's typically the cycle for getting the NCIs out. We have a robust pipeline. We always maintain a very robust pipeline. And it's not a matter of us finding out, trying to find something new to build. It's how do we make sure we're building the best product with the most chances of success to address the SAS or the selectable market that we want to in this space.
Bobby Brooks
Analyst, Northland Capital Markets
so it's a good place to be having more to do than we have time or resources to do allows me to pick the best things to do and the team has done a great job of executing in that regard for sure and maybe just to squeeze one last one in is just so that what am I in these customer conversations or from industry professionals you know what are obviously I'm guessing like the PFAS stuff has came up and that's why you have rolled out a product there what's What are the concerns or problems that they're facing that you're in the process of trying to tackle now?
Robert Banks
President and Chief Executive Officer
So what's happening now and what I'm seeing more is the concerns and questions we get are following news stories. So when there is, in New York City, for example, large leachinella outbreaks, although it's in holding towers and on tops of apartment buildings, it's generated so much more excitement and curiosity and knowledge for is this a problem I need to be concerned about in my building? So those are the problems a lot of people are hearing and passing on to us today. And it's interesting that how little, although Legionella pneumophila has been around since 1976 as a named virus or bacteria, people still don't always understand how it's transmitted, where it's who's susceptible and what to do once you find it. So what we've noticed is just education has been such a key component, being someone that can speak in plain knowledge. And I'm not sure if you've been to many or any of these kind of talks before. Our talks are different. They actually give meaningful information that people can act on and know what to do, and it's not specific to nephros products in general. And it's more of a holistic approach to solving some of these water quality issues. So the problems that we're finding, things we're hearing in some of these trade shows, some of these organizations are all things that we have products to address, whether it's sterile processing or maybe it's emergency eyewash stations. There's tons of new applications that we're hearing about where people don't want bacteria, viruses, endotoxins in their water, and that makes the solution very well suited for technologies in our portfolio.
Bobby Brooks
Analyst, Northland Capital Markets
Well said. Appreciate the color. Congrats on the nice score.
Colby
Conference Call Operator
Thank you. Your next question comes from Jeremy Perlman with Maxim Group. Your line is open.
Jeremy Perlman
Analyst, Maxim Group
Thank you. Good afternoon. So maybe firstly, while you are talking about the education initiatives, how do you evaluate the ROI on that? Are there metrics you're keeping track of? I know you're definitely developing relationships with customers, but what percentage of those customers or potential customers actually transfer? and more into paying customers, just what type of metrics you keep track of.
Robert Banks
President and Chief Executive Officer
That's a very interesting question. I've been actually having a bunch of back and forth dialogue with my director of education recently about that very topic. And as we're looking at KPIs and how do we know what success looks like and are we getting the return and how much should we spend and grow, we are constantly looking at what are the metrics that show us what's happening. Some of the traditional ones you might imagine are maybe attendees to different webinars. We do keep attendance records so we know what organizations people that attend are coming from. Also at trade shows people will come up to the booth and say they attended one of the webinars or When someone comes as a new opportunity, they say they heard about this solution from a webinar. So there's all these intangibles, but as well as just noticing traffic and tracking who is getting to us from where. When we do get new customers, we often ask and track, where did you find us from? Like, how did you get a hold of us? And let's say if there's 37, maybe six of them came from a trade show or maybe... 10 came from just website leads and maybe 20 came from a webinar where they heard about us or a LinkedIn post. And if you're not following us on LinkedIn, there's a ton of great information where you can see where we're solving problems, who we're solving them with. You can see pictures of installations, the RSMs. It's a great way to just keep up to date on more of what we're sharing in industry. and it's important to note because we can't release a press release talking about a particular customer solution. That's never yet year-to-date or existence-to-date been allowed by any of our customers. So the education has generated such an amount of churn and it's a two-way feedback. The questions that get asked in these sessions also give us clues about where people's minds, challenges and to the previous caller's question where we need to focus our next solutions. and I think it's been a fantastic way for us to put ourselves in the forefront when it comes to solving water challenges. The more difficult the problem is, the more likely they are to end up in Nefros' queue. So it's been a good and profitable run and we're looking forward to develop more quantifiable metrics as this department expands and we've got a lot of good ideas coming forward with it to expand in 2027.
Jeremy Perlman
Analyst, Maxim Group
Okay, great. And then maybe if we're just going to shift to the programmatic sales, I know you mentioned that that had growth year over year, but what percentage of customers of your customer base are currently part or contributing to the programmatic sales? I mean, how much runway do you think you have left to grow that?
Robert Banks
President and Chief Executive Officer
I think I understand your question when it comes to the active customers, the 1766 that I mentioned, what percent are programmatic?
Jeremy Perlman
Analyst, Maxim Group
Yeah.
Robert Banks
President and Chief Executive Officer
100%. In order for what we call an active customer to become an active customer, they have to have reordered in some period of time. That eliminates the emergency response customers who had an issue last Friday night at 4.44 p.m. and needed a solution in place by the next Saturday. They only ordered once. They don't become an active customer. So it's kind of a wonky metric how we calculate it because we don't want to artificially inflate it, but it is just customers that are active with us. It also contributes to the way that we track those active customers. And if you were active and suddenly it's X period of time later and you haven't reordered, that tells us that something's gone wrong and prompts a call, a follow-up, and usually will result in a sale because the customer just didn't remember to order or it didn't change their filter on time. So that's a lesson we learned from five or six calls ago where we talked about not getting our fair share of recurring business or recurring revenue because customers just weren't reordering on time. So my key focus, basically starting Q1 last year, had been that programmatic business, and we're not letting it go. those that 1,766 active customers are going to remain active customers as long as we keep doing our job and it's why we have enjoy a pretty high retention rate and continue to grow because customers move and change different places and continue to want to use us and that's one of the main drivers for this growth is people telling a friend.
Jeremy Perlman
Analyst, Maxim Group
Got it. And then just last question, is there a geographic concentration for your overall customer base? Is there a certain regions in the U.S. where they're more concentrated? And then on the flip side, are there areas where you think you could expand into?
Colby
Conference Call Operator
Yeah, good question.
Robert Banks
President and Chief Executive Officer
And yes, you can basically, if you pull up a heat map of where healthcare systems, networks, and facilities are located, patient care, that will mirror almost one-for-one where our customer base is located. We tend to be concentrated in areas where healthcare is concentrated. There are a couple areas where we're not exactly getting our fair share, and we've deployed resources in those areas to kind of increase our penetration. And that's where you'll see initiatives like the Puerto Rico initiative and the New York City initiative that I launched a few quarters ago. So for me, it's coming at it from a market penetration segmentation perspective, understanding are targeted below the market and where we're getting customers and growing market share, that's a driver for where I think that there are opportunities that we may or may not be taking advantage of.
Jeremy Perlman
Analyst, Maxim Group
Okay, great. Thank you for all that information. I'll have that connected. No problem.
Colby
Conference Call Operator
Thank you.
Colby
Conference Call Operator
Again, if you would like to ask a question, please press star, then the number one on your telephone keypad to raise your hand and enter the queue. And with that, ladies and gentlemen, since we have no further questions, so I'd like to turn the conference back over to Robert Banks for closing remarks.
Robert Banks
President and Chief Executive Officer
Thank you, Colby. And again, I can't echo enough how much I'm appreciative of the team for all their hard work. It's been a great quarter. Looking forward to finishing the year strong. And thank you guys for joining. We'll talk to you again soon.
Colby
Conference Call Operator
This concludes today's conference call you may now disconnect.